Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Equity to Asset 0.01
RDNT's Equity to Asset is ranked lower than
91% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. RDNT: 0.01 )
Ranked among companies with meaningful Equity to Asset only.
RDNT' s 10-Year Equity to Asset Range
Min: -0.85  Med: -0.17 Max: 0.01
Current: 0.01
-0.85
0.01
Interest Coverage 1.25
RDNT's Interest Coverage is ranked lower than
95% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. RDNT: 1.25 )
Ranked among companies with meaningful Interest Coverage only.
RDNT' s 10-Year Interest Coverage Range
Min: 0.22  Med: 0.79 Max: 1.33
Current: 1.25
0.22
1.33
F-Score: 6
Z-Score: 1.23
M-Score: -2.84
WACC vs ROIC
5.85%
5.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 6.00
RDNT's Operating margin (%) is ranked higher than
63% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. RDNT: 6.00 )
Ranked among companies with meaningful Operating margin (%) only.
RDNT' s 10-Year Operating margin (%) Range
Min: -116.39  Med: 7.20 Max: 16.68
Current: 6
-116.39
16.68
Net-margin (%) 1.27
RDNT's Net-margin (%) is ranked higher than
55% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.26 vs. RDNT: 1.27 )
Ranked among companies with meaningful Net-margin (%) only.
RDNT' s 10-Year Net-margin (%) Range
Min: -135.47  Med: -2.47 Max: 13.48
Current: 1.27
-135.47
13.48
ROE (%) 52.10
RDNT's ROE (%) is ranked higher than
98% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.76 vs. RDNT: 52.10 )
Ranked among companies with meaningful ROE (%) only.
RDNT' s 10-Year ROE (%) Range
Min: 52.1  Med: 52.10 Max: 52.1
Current: 52.1
ROA (%) 1.25
RDNT's ROA (%) is ranked higher than
57% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.65 vs. RDNT: 1.25 )
Ranked among companies with meaningful ROA (%) only.
RDNT' s 10-Year ROA (%) Range
Min: -39.36  Med: -2.52 Max: 13.24
Current: 1.25
-39.36
13.24
ROC (Joel Greenblatt) (%) 17.32
RDNT's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.66 vs. RDNT: 17.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RDNT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -44.17  Med: 15.97 Max: 34.66
Current: 17.32
-44.17
34.66
Revenue Growth (3Y)(%) 3.30
RDNT's Revenue Growth (3Y)(%) is ranked lower than
61% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. RDNT: 3.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RDNT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 1.1  Med: 8.70 Max: 25.5
Current: 3.3
1.1
25.5
EBITDA Growth (3Y)(%) -5.70
RDNT's EBITDA Growth (3Y)(%) is ranked lower than
64% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. RDNT: -5.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RDNT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -43.1  Med: 7.65 Max: 169.2
Current: -5.7
-43.1
169.2
EPS Growth (3Y)(%) -46.00
RDNT's EPS Growth (3Y)(%) is ranked lower than
87% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. RDNT: -46.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RDNT' s 10-Year EPS Growth (3Y)(%) Range
Min: -46  Med: -14.20 Max: 28.4
Current: -46
-46
28.4
» RDNT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

RDNT Guru Trades in Q2 2014

Jim Simons 798,900 sh (New)
Paul Tudor Jones 10,084 sh (New)
» More
Q3 2014

RDNT Guru Trades in Q3 2014

Paul Tudor Jones Sold Out
Jim Simons 532,800 sh (-33.31%)
» More
Q4 2014

RDNT Guru Trades in Q4 2014

Jim Simons 337,200 sh (-36.71%)
» More
Q1 2015

RDNT Guru Trades in Q1 2015

Paul Tudor Jones 36,100 sh (New)
Jim Simons 321,800 sh (-4.57%)
» More
» Details

Insider Trades

Latest Guru Trades with RDNT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 35.36
RDNT's P/E(ttm) is ranked higher than
50% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.70 vs. RDNT: 35.36 )
Ranked among companies with meaningful P/E(ttm) only.
RDNT' s 10-Year P/E(ttm) Range
Min: 1.43  Med: 13.60 Max: 46.63
Current: 35.36
1.43
46.63
Forward P/E 10.71
RDNT's Forward P/E is ranked higher than
91% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.83 vs. RDNT: 10.71 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 35.50
RDNT's PE(NRI) is ranked higher than
51% of the 85 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.20 vs. RDNT: 35.50 )
Ranked among companies with meaningful PE(NRI) only.
RDNT' s 10-Year PE(NRI) Range
Min: 1.44  Med: 13.55 Max: 47.37
Current: 35.5
1.44
47.37
P/B 61.99
RDNT's P/B is ranked lower than
98% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.61 vs. RDNT: 61.99 )
Ranked among companies with meaningful P/B only.
RDNT' s 10-Year P/B Range
Min: 35.71  Med: 64.00 Max: 930
Current: 61.99
35.71
930
P/S 0.42
RDNT's P/S is ranked higher than
97% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.22 vs. RDNT: 0.42 )
Ranked among companies with meaningful P/S only.
RDNT' s 10-Year P/S Range
Min: 0.07  Med: 0.19 Max: 1.07
Current: 0.42
0.07
1.07
PFCF 11.00
RDNT's PFCF is ranked higher than
92% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.75 vs. RDNT: 11.00 )
Ranked among companies with meaningful PFCF only.
RDNT' s 10-Year PFCF Range
Min: 1.08  Med: 3.93 Max: 209.67
Current: 11
1.08
209.67
POCF 3.71
RDNT's POCF is ranked higher than
96% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.69 vs. RDNT: 3.71 )
Ranked among companies with meaningful POCF only.
RDNT' s 10-Year POCF Range
Min: 0.56  Med: 1.75 Max: 25.17
Current: 3.71
0.56
25.17
EV-to-EBIT 16.68
RDNT's EV-to-EBIT is ranked higher than
68% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.37 vs. RDNT: 16.68 )
Ranked among companies with meaningful EV-to-EBIT only.
RDNT' s 10-Year EV-to-EBIT Range
Min: 11.4  Med: 16.60 Max: 37.2
Current: 16.68
11.4
37.2
PEG 50.71
RDNT's PEG is ranked lower than
95% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. RDNT: 50.71 )
Ranked among companies with meaningful PEG only.
RDNT' s 10-Year PEG Range
Min: 0.18  Med: 1.24 Max: 169.18
Current: 50.71
0.18
169.18
Shiller P/E 28.96
RDNT's Shiller P/E is ranked higher than
51% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.42 vs. RDNT: 28.96 )
Ranked among companies with meaningful Shiller P/E only.
RDNT' s 10-Year Shiller P/E Range
Min: 9.44  Med: 31.11 Max: 51.5
Current: 28.96
9.44
51.5
Current Ratio 1.46
RDNT's Current Ratio is ranked lower than
80% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. RDNT: 1.46 )
Ranked among companies with meaningful Current Ratio only.
RDNT' s 10-Year Current Ratio Range
Min: 0.15  Med: 1.06 Max: 1.72
Current: 1.46
0.15
1.72
Quick Ratio 1.46
RDNT's Quick Ratio is ranked lower than
70% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. RDNT: 1.46 )
Ranked among companies with meaningful Quick Ratio only.
RDNT' s 10-Year Quick Ratio Range
Min: 0.15  Med: 1.06 Max: 1.72
Current: 1.46
0.15
1.72
Days Sales Outstanding 76.63
RDNT's Days Sales Outstanding is ranked lower than
63% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.88 vs. RDNT: 76.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
RDNT' s 10-Year Days Sales Outstanding Range
Min: 53.25  Med: 75.14 Max: 128.88
Current: 76.63
53.25
128.88

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 2.21
RDNT's Price/Median PS Value is ranked lower than
88% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. RDNT: 2.21 )
Ranked among companies with meaningful Price/Median PS Value only.
RDNT' s 10-Year Price/Median PS Value Range
Min: 0.34  Med: 1.06 Max: 5.1
Current: 2.21
0.34
5.1
Earnings Yield (Greenblatt) (%) 5.98
RDNT's Earnings Yield (Greenblatt) (%) is ranked higher than
84% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. RDNT: 5.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RDNT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 2.7  Med: 6.00 Max: 8.8
Current: 5.98
2.7
8.8
Forward Rate of Return (Yacktman) (%) -4.58
RDNT's Forward Rate of Return (Yacktman) (%) is ranked lower than
83% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.08 vs. RDNT: -4.58 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
RDNT' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -5.9  Med: 7.80 Max: 100.8
Current: -4.58
-5.9
100.8

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:PQIA.Germany,
RadNet Inc is incorporated in Delaware and has been in business since 1985. The Company provides freestanding, fixed-site outpatient diagnostic imaging services in the United States based on number of locations and annual imaging revenue. At December 31, 2012, it operated directly or indirectly through joint ventures, 250 centers located in California, Maryland, Florida, Delaware, New Jersey, Rhode Island and New York. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Diagnostic imaging involves the use of non-invasive procedures to generate representations of internal anatomy and function that can be recorded on film or digitized for display on a video monitor. Diagnostic imaging procedures facilitate the early diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often minimizing the cost and amount of care for patients. Diagnostic imaging procedures include MRI, CT, PET, nuclear medicine, ultrasound, mammography, X-ray and fluoroscopy. While X-ray remains the commonly performed diagnostic imaging procedure, the growing and higher margin procedures are MRI, CT and PET. The rapid growth in PET scans is attributable to the increasing recognition of the efficacy of PET scans in the diagnosis and monitoring of cancer. The number of MRI and CT scans performed annual in the United States continues to grow due to their wider acceptance by physicians and payors, an increasing number of applications for their use and a general increase in demand due to the aging population. The Companys sales and marketing team employs a multi-pronged approach to marketing, including physician, payor and sports marketing programs. The market for diagnostic imaging services is highly competitive. The Company competes locally with groups of radiologists, established hospitals, clinics and other independent organizations that own and operate imaging equipment. Its competitors include Alliance Healthcare Services, Inc., Diagnostic Imaging Group and several smaller regional competitors.
» More Articles for RDNT

Headlines

Articles On GuruFocus.com
Doral Financial Corp (DRL) Skyrockets with Unusual Market Activity, RadNet Inc (RDNT) Soars on Resul May 12 2014 
Weekly 3-Year Lows Highlight: FWM, FST, LAND, RDNT Jan 13 2014 
research Jun 12 2011 
research Jun 12 2011 
RadNet Inc. Reports Operating Results (10-K) Mar 11 2011 
RadNet Inc. Reports Operating Results (10-Q) Aug 09 2010 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 22,200 Shares Sep 22 2009 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 77,800 Shares Sep 21 2009 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 69,215 Shares Sep 21 2009 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 30,785 Shares Sep 18 2009 

More From Other Websites
RadNet, Inc. Announces Date of Its Second Quarter 2015 Financial Results Conference Call Jul 31 2015
RADNET, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to... Jun 12 2015
RadNet, Inc. to Present at the Barclays Capital High Yield Bond & Syndicated Loan Conference on June... Jun 10 2015
Bio-Reference Laboratories, Inc.: Leads amongst peers with strong fundamentals Jun 06 2015
RadNet, Inc. to Present at the Jefferies 2015 Global Healthcare Conference on June 4, 2015 Jun 01 2015
RADNET, INC. Financials May 16 2015
10-Q for RadNet, Inc. May 13 2015
CORRECTION -- RadNet Reports First Quarter Financial Results and Adjusts Upwards 2015 Guidance... May 12 2015
RADNET, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 12 2015
RADNET, INC. Files SEC form 10-Q, Quarterly Report May 11 2015
Q1 2015 RadNet Inc Earnings Release - Before Market Open May 11 2015
RadNet reports 1Q loss May 11 2015
RadNet reports 1Q loss May 11 2015
RadNet Reports First Quarter Financial Results and Adjusts Upwards 2015 Guidance Ranges May 11 2015
RADNET, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... May 01 2015
RadNet Adds Eight Prime Manhattan Locations to Imaging Center Holdings Apr 15 2015
The Zacks Analyst Blog Highlights: Caterpillar, Procter & Gamble, Horizon Pharma, RadNet and PRA... Apr 07 2015
Jobs Data Dips: 3 Healthy Picks - Analyst Blog Apr 06 2015
RadNet Surges On B. Riley Initiation Mar 26 2015
RADNET, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK